Day One Biopharmaceuticals (DAWN) EBIAT: 2023-2025
Historic EBIAT for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to -$19.7 million.
- Day One Biopharmaceuticals' EBIAT fell 153.26% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$151.8 million, marking a year-over-year decrease of 80.04%. This contributed to the annual value of -$95.5 million for FY2024, which is 49.45% up from last year.
- According to the latest figures from Q3 2025, Day One Biopharmaceuticals' EBIAT is -$19.7 million, which was up 34.94% from -$30.3 million recorded in Q2 2025.
- Over the past 5 years, Day One Biopharmaceuticals' EBIAT peaked at $37.0 million during Q3 2024, and registered a low of -$65.7 million during Q4 2024.
- Its 3-year average for EBIAT is -$32.5 million, with a median of -$39.2 million in 2023.
- Per our database at Business Quant, Day One Biopharmaceuticals' EBIAT surged by 180.25% in 2024 and then crashed by 588.04% in 2025.
- Day One Biopharmaceuticals' EBIAT (Quarterly) stood at -$54.5 million in 2023, then declined by 20.55% to -$65.7 million in 2024, then plummeted by 153.26% to -$19.7 million in 2025.
- Its last three reported values are -$19.7 million in Q3 2025, -$30.3 million for Q2 2025, and -$36.0 million during Q1 2025.